Publications by the researcher in collaboration with María Chaparro Sánchez (22)

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

2022

  1. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  2. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  3. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42

2020

  1. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

  3. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428

2018

  1. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study

    American Journal of Gastroenterology, Vol. 113, Núm. 3, pp. 396-403

2017

  1. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

    Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402

  2. Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease

    Journal of Crohn's and Colitis, Vol. 11, Núm. 7, pp. 792-800

  3. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131

  4. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study

    American Journal of Gastroenterology, Vol. 112, Núm. 11, pp. 1709-1718

  5. Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 11, Núm. 12, pp. 1430-1439

2016

  1. Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent

    Digestive and Liver Disease, Vol. 48, Núm. 6, pp. 613-619

  2. Outcomes of medical and surgical therapy for entero-urinary fistulas in Crohn's disease

    Journal of Crohn's and Colitis, Vol. 10, Núm. 6, pp. 657-662

2013

  1. Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients

    Inflammatory Bowel Diseases, Vol. 19, Núm. 7, pp. 1404-1410

2012

  1. Effectiveness of infliximab after adalimumab failure in Crohn's disease

    World Journal of Gastroenterology, Vol. 18, Núm. 37, pp. 5219-5224

  2. Long-term durability of response to adalimumab in Crohn's disease

    Inflammatory Bowel Diseases, Vol. 18, Núm. 4, pp. 685-690